Compare RGS & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RGS | MDXH |
|---|---|---|
| Founded | 1922 | 2003 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 72.6M | 68.7M |
| IPO Year | 1994 | 2021 |
| Metric | RGS | MDXH |
|---|---|---|
| Price | $29.00 | $0.20 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $1.80 |
| AVG Volume (30 Days) | 4.7K | ★ 220.4K |
| Earning Date | 11-11-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.41 | N/A |
| Revenue | ★ $224,485,000.00 | N/A |
| Revenue This Year | N/A | $5.10 |
| Revenue Next Year | $1.68 | $13.22 |
| P/E Ratio | $12.11 | ★ N/A |
| Revenue Growth | ★ 6.83 | N/A |
| 52 Week Low | $19.31 | $0.40 |
| 52 Week High | $30.93 | $5.33 |
| Indicator | RGS | MDXH |
|---|---|---|
| Relative Strength Index (RSI) | 52.89 | 20.10 |
| Support Level | $26.23 | N/A |
| Resistance Level | $29.65 | $0.64 |
| Average True Range (ATR) | 0.59 | 0.06 |
| MACD | -0.05 | -0.02 |
| Stochastic Oscillator | 52.94 | 0.47 |
Regis Corporation franchises, owns, and operates hair care salons, mainly in North America, with licensed locations in the U.K. Its salons provide haircutting, styling, shampooing and conditioning, hair coloring and related services, and also sell hair care and beauty products. The company's primary brands include Supercuts, SmartStyle, Cost Cutters, First Choice Haircutters and Roosters. Its operating segments are Franchise and Company-Owned, with the majority of its revenue generated from the Franchise segment.
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.